Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
Peptide Analogs
A research peptide blend of a long-acting acylated peptide analog and the pentapeptide ipamorelin.
Reviewed by Dr. James Whitfield, PharmD · Published · Last reviewed · For research use only.
Peptide blend
Molecular formula
C225H348N48O68
Molecular weight
~4,814 g/mol
CAS number
2023788-19-2
Sequence
Modified 39-residue GIP-based peptide; Aib at positions 2 and 13; C-terminal amide; Lys20 C20 fatty-diacid via gamma-Glu and AEEA linkers
Molecular formula
C38H49N9O5
Molecular weight
711.9 g/mol
CAS number
170851-70-4
Sequence
Aib-His-D-2-Nal-D-Phe-Lys-NH2
Combines two peptides characterized in structural studies of distinct GPCR classes. The LUV TRZ component is a long-acting, acylated peptide whose C20 fatty-diacid side chain confers reversible albumin binding, extending circulatory half-life; in cryo-EM studies it adopts an α-helical conformation in complex with class B G-protein-coupled receptors. Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) characterized in structural studies of a class A G-protein-coupled receptor, where its N-terminal Aib and D-2Nal residues occupy hydrophobic receptor pockets and the Lys-NH2 terminus makes polar contacts. Because the two components are characterized at different GPCR classes, no single structural target describes the blend.
Lyophilized
≤ −20 °C with desiccant
protect from light and moisture.
The acylated GIP-analog component may aggregate if mishandled; Aliquot both components; protect from light.
Reviews
Galindo RJ, et al. (2026). Diabetes Ther
Shiimura Y, et al. (2025). Front Mol Neurosci
Karagiannis T, et al. (2022). Diabetologia
Reviews
Min T, Bain SC. (2021). Diabetes Ther
Liu QK. (2024). Front Endocrinol
Abizaid A, Hougland JL. (2020). Trends Endocrinol Metab
Davis TR, et al. (2021). Open Biol
Clinical
Gobburu JV, et al. (1999). Pharm Res
Primary research
Liu H, et al. (2021). Nat Commun
Zhao F, et al. (2022). Nat Commun
Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. (1998). Eur J Endocrinol
Willard FS, et al. (2020). JCI Insight
Sun B, et al. (2022). Proc Natl Acad Sci USA
Samms RJ, et al. (2021). J Clin Invest
Qin J, et al. (2022). Nat Commun
Svensson J, et al. (2000). J Endocrinol
Andersen NB, et al. (2001). Growth Horm IGF Res
Johansen PB, et al. (1999). Growth Horm IGF Res
Venkova K, et al. (2009). J Pharmacol Exp Ther
Johansen PB, et al. (1998). Xenobiotica
Research Use Only
These products are intended for research purposes only and are not for human consumption. Not FDA approved. Not intended to diagnose, treat, cure, or prevent any disease.
| Compound | Type | Molecular weight | CAS number |
|---|---|---|---|
| LUV TRZ / IpamorelinThis page | Peptide blend | — | — |
| LUV RT | Synthetic peptide (acylated, 39 residues) | ~4,731 Da | 2381089-83-2 |
| LUV SM | Synthetic peptide (acylated, 31 residues) | ~4,114 g/mol | 910463-68-2 |
| LUV TRZ2 | Synthetic linear peptide (acylated, 39 residues) | ~4,814 g/mol | 2023788-19-2 |
| AOD-9604 | Synthetic peptide (cyclic, 16 residues) | ~1,815 g/mol | 221231-10-3 |
Comparison of laboratory reference specifications only. For research use only; not a therapeutic comparison.
Quality & methods